AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms
AstraZeneca: The Late Entrant Against TrodelvyThin moat
Gilead Sciences (GILD) — moat facet
AstraZeneca's Datroway entered Trodelvy's first-line breast cancer market in May 2026 claiming an overall-survival benefit Gilead's label does not state.
AstraZeneca is not a rival in HIV; it is the competitor aimed at Gilead's most expensive acquisition. Trodelvy, bought with Immunomedics for $20.6 billion in 20201, is a TROP2-directed antibody drug conjugate. On 26 May 2026 AstraZeneca's Datroway, developed with Daiichi Sankyo, was approved in the United States for first-line metastatic triple-negative breast cancer in patients who are not candidates for PD-1/PD-L1 inhibitors2.
AstraZeneca's announcement claims Datroway is "the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting" against chemotherapy3. That is AstraZeneca's claim, not an independent finding, but it is the kind of label language that moves prescribers.
Gilead is ahead on revenue and arrived at the same line of therapy at the same time. Trodelvy received its own FDA approval for first-line triple-negative breast cancer in the second quarter of 2026, as a single agent or with Keytruda4. It sold $457 million in that quarter, up 26%5, and $1,397 million in 20256. Datroway's product sales were $43 million in the first quarter of 20267.
The relationship is that of an incumbent with a small lead and a newcomer with a strong claim. Gilead's lead in this market is years old; AstraZeneca's is a few months.
Trodelvy has had setbacks of its own that a rival can exploit. Its 2025 growth of 6% was "partially offset by the indication withdrawal in bladder cancer treatment"8, and the lung-cancer study with Merck was stopped in 20269. Breast cancer is now Trodelvy's main market, which makes a direct TROP2 rival there more dangerous than it would be to a drug with several indications.
The contest will be settled in first-line prescriptions over the next two years. If Datroway's quarterly sales pass a quarter of Trodelvy's before the end of 2027, the late entrant will be taking the market Gilead paid for.
Datroway approved 26 May 2026 in first-line TNBC.
The size of the lead; Datroway above a quarter of Trodelvy before end-2027 would mean the newcomer is winning.
Source: Gilead Sciences Q2 2026 results release ↗- ReportedTrodelvy, bought with Immunomedics for $20.6 billion in 2020, is a TROP2-directed antibody drug conjugate.Gilead Sciences Form 10-K for 2020 - the Immunomedics ($20.6 billion) and Forty Seven (about $4.7 billion) acquisitions, acquired IPR&D and the 94.7% effective tax rate. — FY2020 · publ. February 2021 · source ↗
- ReportedOn 26 May 2026 AstraZeneca's Datroway, developed with Daiichi Sankyo, was approved in the United States for first-line metastatic triple-negative breast cancer in patients who are not candidates for PD-1/PD-L1 inhibitors.AstraZeneca Form 6-K of 26 May 2026 - US approval of Datroway as the first TROP2-directed antibody drug conjugate for first-line metastatic triple-negative breast cancer in patients who are not PD-1/PD-L1 inhibitor candidates. — May 2026 · publ. 26 May 2026 · source ↗
- ReportedAstraZeneca's announcement claims Datroway is "the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting" against chemotherapy.AstraZeneca Form 6-K of 26 May 2026 - US approval of Datroway as the first TROP2-directed antibody drug conjugate for first-line metastatic triple-negative breast cancer in patients who are not PD-1/PD-L1 inhibitor candidates. — May 2026 · publ. 26 May 2026 · source ↗
- ReportedTrodelvy received its own FDA approval for first-line triple-negative breast cancer in the second quarter of 2026, as a single agent or with Keytruda.Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - pipeline, regulatory and business development updates. — Q2 2026 · publ. 4 August 2026 · source ↗
- ReportedIt sold $457 million in that quarter, up 26%, and $1,397 million in 2025.Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - revenue by product and product group and the drivers of each. — Q2 2026 · publ. 4 August 2026 · source ↗
- ReportedIt sold $457 million in that quarter, up 26%, and $1,397 million in 2025.Gilead Sciences Form 10-K for 2025 - revenue by product, product group and region (Note 2) and the MD&A discussion of product sales. — FY2025 · publ. 24 February 2026 · source ↗
- ReportedDatroway's product sales were $43 million in the first quarter of 2026.AstraZeneca first-quarter 2026 results, Form 6-K - Datroway product sales of $43 million. — Q1 2026 · publ. April 2026 · source ↗
- ReportedIts 2025 growth of 6% was "partially offset by the indication withdrawal in bladder cancer treatment", and the lung-cancer study with Merck was stopped in 2026.Gilead Sciences Form 10-K for 2025 - Item 1 business and the revenue-by-product table: products, programs, employees and manufacturing. — FY2025 · publ. 24 February 2026 · source ↗
- ReportedIts 2025 growth of 6% was "partially offset by the indication withdrawal in bladder cancer treatment", and the lung-cancer study with Merck was stopped in 2026.Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - pipeline, regulatory and business development updates. — Q2 2026 · publ. 4 August 2026 · source ↗